미국 백신 시장 규모는 2025-2032년 예측 기간 동안 5.70%의 CAGR로 2024년 222억 3,000만 달러에서 2032년 346억 4,000만 달러로 확대될 것으로 예상됩니다.
미국이 세계 백신 시장을 선도하는 배경에는 탄탄한 의료 시스템, 높은 예방접종률, 막대한 연구개발비가 있으며, Pfizer, Moderna, Merck와 같은 최고 수준의 백신 제조업체의 존재도 이 지역의 리더십을 뒷받침하고 있습니다. 이들 기업은 특히 mRNA 기술 분야에서 백신 개발을 선도하고 있습니다. 캐나다의 예방접종 프로그램이나 미국의 Vaccines for Children(VFC) 프로그램과 같은 정부 프로그램은 백신 접종의 보급을 보장합니다.
유리한 상환 규정과 높은 의료비 지출이 시장을 더욱 뒷받침하고 있으며, FDA와 캐나다 보건부는 백신의 안전성과 효능을 보장하고 있으며, 이 지역은 강력한 규제 프레임워크의 혜택을 누리고 있습니다. 미국과 캐나다가 백신의 제조, 생산, 유통을 주도하고 있기 때문에 COVID-19 사태 동안 미국은 시장에서의 우위를 더욱 강화했습니다. 예를 들어, B형 간염 재단은 미국 질병예방통제센터(CDC)가 업데이트한 성인 B형 간염 백신 가이드라인을 강력히 지지하고 있습니다. 재단은 미국 내 수백만 성인의 유해한 바이러스에 대한 백신 접종률을 높이기 위해 전문가 패널과 적극적으로 협력하여 이 권고안이 성공적으로 시행될 수 있도록 지원하고 있습니다. 미국에서는 약 240만 명이 만성 B형 간염에 감염되어 매년 수천 명의 목숨을 앗아가고 있습니다.
미국의 백신 시장에 대해 조사했으며, 시장 개요와 함께 기술별, 투여 경로별, 적응증별, 연령대별, 유통 채널별, 지역별 동향, 시장 진입 기업 프로파일 등의 정보를 전해드립니다.
United States vaccines market is projected to witness a CAGR of 5.70% during the forecast period 2025-2032, growing from USD 22.23 billion in 2024 to USD 34.64 billion in 2032.
The United States leads the world market for vaccines because of a robust healthcare system, high immunization rates, and substantial R&D expenditures. The presence of top vaccine producers like Pfizer, Moderna, and Merck aids the region's leadership. These businesses are leading the way in vaccine development, especially in the field of mRNA technology. Widespread vaccination distribution is guaranteed by government programs like Canada's immunization programs and the United States' Vaccines for Children (VFC) program. Advantageous reimbursement regulations and high healthcare spending further support the market. The FDA and Health Canada guarantee the safety and effectiveness of vaccines, and the region also benefits from robust regulatory frameworks. United States's dominant position in the market further improved during the COVID-19 epidemic, as the United States and Canada spearheaded the creation, manufacturing, and distribution of vaccines. With continuous advancements in vaccine technology and rising investments in immunization programs, the market will grow in the United States The Hepatitis B Foundation, for example, is a strong supporter of the United States Centers for Disease Control and Prevention's (CDC) updated guidelines for adult hepatitis B vaccine. To increase vaccine coverage against this harmful virus among millions of American adults, the Foundation is actively working with a panel of experts to support the successful implementation of these recommendations. About 2.4 million people in the United States have chronic hepatitis B, and the illness claims thousands of lives each year.
Technological Advancements Boosting Market Growth
The expansion of the vaccine market in the United States is boosting by transforming the processes of research, development, and production. Pfizer, Inc., BioNTech SE, and Moderna, Inc. were the first to create mRNA technology, which has raised the bar for quick vaccine production and allowed quicker reactions to new illnesses. By predicting virus alterations, optimizing clinical trials, and speeding up drug discovery, artificial intelligence (AI) and machine learning are simplifying vaccination research. Innovations in automation and bioprocessing, like cell-based manufacturing and single-use bioreactors, are increasing the scalability and efficiency of vaccine production. Through increased stability and immune response activation, nanotechnology is increasing vaccine delivery. Improved vaccine distribution and storage are made possible by sophisticated cold chain logistics, such as intelligent temperature monitoring and freeze-drying methods. Furthermore, the creation of next-generation vaccines is being aided by synthetic biology and CRISPR gene-editing technology. For instance, Emergent BioSolutions Inc. announced in July 2023, that the United States Food and Drug Administration (FDA) had approved CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs. With ongoing innovation in biotechnology and digital healthcare, the United States vaccine market is poised for sustained growth and rapid advancements in immunization strategies. For instance, in February 2024, researchers from the University at Buffalo in the United States developed a promising recombinant flu vaccine using Nano-liposome technology.
Rising Numbers of Chronic Diseases Fueling Market Growth
Since people with diabetes, cancer, cardiovascular disease, and chronic respiratory illnesses are more likely to get infections, the growing frequency of chronic diseases is a significant factor driving the United States vaccination industry. These individuals are particularly vulnerable to vaccine-preventable illnesses like hepatitis, pneumonia, and influenza because they frequently have compromised immune systems. Because of this, medical professionals promote vaccination as a preventative strategy to lower hospitalizations and further possible problems. Pharmaceutical firms are spending money on customized vaccinations for people with weakened immune systems, such as enhanced influenza and pneumococcal vaccines. Furthermore, the growing prevalence of chronic diseases has sped up the creation of therapeutic vaccines, such those for cancer, which aim to boost the immune system's ability to combat malignancies. Government initiatives and insurance coverage for adult vaccinations further support market growth. With chronic disease cases rising due to aging populations and lifestyle factors, the demand for vaccines in the United States is expected to continue growing. For instance, in 2023, the United States reported 9,633 cases of TB disease. This represents an increase in case count of 15.6% compared with 2022.
Investments and Fundings Fueling Market Growth
Large investments made by the United States government and pharmaceutical companies are propelling the expansion of the United States vaccines market by speeding up research, development, and production. Rapid vaccine invention, especially in mRNA technology, has been made possible by government programs like Operation Warp Speed and continuous financing from organizations like the National Institutes of Health (NIH) and Biomedical Advanced Research and Development Authority (BARDA). These expenditures fund extensive immunization efforts and aid the fight against newly emerging infectious diseases. Additionally, pharmaceutical firms such as Pfizer Inc., Moderna Inc., and Merck Co. are making significant investments in next-generation vaccines to prevent respiratory infections, cancer, and other illnesses. Partnerships between the public and private sectors improve vaccine distribution and accessibility even more. For instance, CSL Limited established a new state-of-the-art vaccine R&D centre in Massachusetts. The R&D facility is equipped with 54,000 square feet of lab space, comprising Biosafety Level 3. The United States vaccines market is growing due to consistent funding support and strategic partnerships, which guarantees quicker reactions to health risks and better vaccination accessibility for a range of demographics.
Future Market Scenario (2025-2032F)
One of the main factors contributing to the anticipated growth of the vaccines market is the increasing demand for treatment options to ensure patient safety by delivering the right quality of drug or any other such chemical product. Not only that but the rising population and cases of chronic diseases such as cancer, is also a factor that will always propel market growth in future. Given that technology is advancing, we can expect cutting-edge technology in the area also. Players in this market are expanding at an un-paralleled rate, introducing cost-effective and efficient technologies. For instance, in August 2023, Pfizer, Inc., received the United States FDA approval for ABRYSVO, used for the prevention of lower respiratory tract disease (LRTD) and severe LRTD cause in infants from birth upto six months of age.
Key Players Landscape and Outlook
Key players in the vaccines industry utilize strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing big-cap industry players to increase their presence and, therefore, find new opportunities in this market.
For example, accessibility for people ages 2 to 49 was improved in September 2024 when the Food and Drug Administration (FDA) authorized the FluMist for self- or caregiver-administration. This permission made immunizations more convenient because they can now be given at home following a screening procedure. FluMist is authorized to protect people aged 2 to 49 from influenza illness brought on by influenza virus subtypes A and B.
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.